B. Gumuscu
AuthID: R-00K-GM8
1
TITLE: Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040
AUTHORS: Soulieres, D.; Harrington, K. J.; Le Tourneau, C.; Silva, J. D.; Licitra, L. F.; Ahn, M J.; Soria, A.; Machiels, J P.; Mach, N.; Mehra, R.; Burtness, B.; Lin, J.; Lerman, N.; Gumuscu, B.; Cohen, E. E. W.;
PUBLISHED: 2022, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 33, ISSUE: 7
AUTHORS: Soulieres, D.; Harrington, K. J.; Le Tourneau, C.; Silva, J. D.; Licitra, L. F.; Ahn, M J.; Soria, A.; Machiels, J P.; Mach, N.; Mehra, R.; Burtness, B.; Lin, J.; Lerman, N.; Gumuscu, B.; Cohen, E. E. W.;
PUBLISHED: 2022, SOURCE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 33, ISSUE: 7
INDEXED IN: 
WOS
WOS